Analysis of the real efficacy of Taletrectinib in the treatment of lung cancer

Taletrectinib (Taletrectinib), as a new generation of ROS1 targeted inhibitors, has shown excellent clinical efficacy in the treatment of ROS1 fusion-positive non-small cell lung cancer (NSCLC) patients. According to clinical research data from TRUST-I and TRUST-II in China and across multiple centers around the world, talatinib has been shown to be effective in patients who have not received ROS1< Among patients treated with /span>inhibitors, the objective response rate (ORR) is as high as 85%~90% and most patients can observe tumor shrinkage within a short period of time after treatment. This shows that it has extremely strong tumor control ability and is particularly suitable for first-line treatment of ROS1-positive lung cancer patients.

A major advantage of talatinib is that it still has good efficacy in patients who have previously failed treatment with first-generation ROS1 inhibitors such as crizotinib. In the TRUST-II study, the ORR of such patients who had failed previous treatments could still reach about 52%~62%, the median progression-free survival (PFS) exceeds 7 months, and some patients can reach 10 months or more. This is of great significance for a patient group with fewer treatment options after resistance to first-line ROS1 targeted drugs.

Among ROS1 positive lung cancer patients, brain metastasis is a common clinical problem. Taritinib has demonstrated good central nervous system penetration in clinical trials and has also shown significant efficacy in patients with brain metastases. Multiple case studies have confirmed that the drug can significantly shrink metastatic lesions in the brain, and some patients have complete remission of brain metastases. This characteristic makes talatinib particularly valuable in the treatment of brain metastases from ROS1-positive lung cancer.

In addition to its outstanding efficacy, the safety and tolerability of talatinib are also widely praised. Adverse reactions in most patients are mild to moderate, such as fatigue, mild gastrointestinal discomfort, or elevated liver enzymes, and treatment interruption is rarely necessary due to side effects. This means that talatinib is not only suitable for short-term remission of the disease, but also has the potential for long-term maintenance treatment forROS1A more sustainable treatment option for patients with fusion-positive lung cancer. Taken together, talatinib is becoming a promising precision medication option for this population.

Reference materials:https://www.fda.gov/drugs/